ClinicalTrials.gg
RecruitingNCT07238608UPRISEUpdated Nov 16, 2026

Impact of UFPs and MNPs on Fetal Health

An observational study in Pregnant Women, sponsored by Alba Ruiz Gaitán. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Alba Ruiz Gaitán · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 16, 2026Primary outcomes revisedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,600
Ages
18 Years and older
Sex
Female
01

Study summary

This project aims at unravelling mechanisms by which exposure to air pollution (in particular Ultrafine Particulate (UFP, PM0.1), and micro nano plastic's) interferes with the normal foetus development, with a short-term causal effect in higher likeliness of preterm delivery which, in consequence, precondition a higher likeliness to suffer non-communicable diseases (NCD) later in the life.

Read the detailed description

The characteristics of this study population are as follows:

  1. Case-control design The study includes 1600 participants, providing a substantial sample for analysis. The focus is on newborns (age 0), making the study particularly relevant for understanding factors and outcomes related to this very early stage of life. The sex of the participants is expected to be randomly distributed. A control arm of full-term neonates (>37 weeks) will be recruited for a 1:2 ratio in Greece and Spain.
  2. Personal Exposure Monitoring PEM Substudy:

The study consists of 150 mothers, with 50 from each location. All participants are females aged over 18 years. The sex of the participants is expected to be randomly distributed.

02

Conditions studied

  • Pregnant Women

Keywords

  • non-communicable diseases
  • Ultrafine Particulate
  • micro nano plastics
03

In context

Noncommunicable Diseases

146 studies on the registry are indexed under Noncommunicable Diseases; 57 are open to participants now.

This study's planned enrollment of 1,600 is close to the median of 1,674 across 48 observational studies indexed under Noncommunicable Diseases.

Browse Noncommunicable Diseases studies →

Lead sponsor

This is the only study on the registry with Alba Ruiz Gaitán as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant mothers will be recruited at the first antenatal visit (around eight weeks of gestation).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agreement to sign the ;
  • Non-smoking mothers and no exposure to environmental (second-hand) smoke (smoking influences UFP measurements);
  • ≥18 years old (mothers have to place sensors, mothers with childhood pregnancies may live at their parental home);
  • Not expecting to terminate the pregnancy (no measurements of the child);
  • Having resided in the geographical area of research for a minimum period of 1 year (to be eligible for modeling exposures).

Exclusion criteria

Exclusion Criteria:

  • First visit after 11 weeks of gestation (to ensure 2-week monitoring in the first trimester);
  • Pregnancy complications that limit exposure measurements in urine (because it may cause polyuria, for example, gestational diabetes);
  • Known kidney disease (might influence exposure measurements in urine);
  • Multiple pregnancy (twin or more pregnancies may have a higher risk for complications or preterm birth, no measurements in the last trimester).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,600 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Case-control design

    The study includes 1600 participants, providing a substantial sample for analysis. The focus is on newborns (age 0), making the study particularly relevant for understanding factors and outcomes related to this very early stage of life. The sex of the participants is expected to be randomly distributed. A control arm of full-term neonates (\>37 weeks) will be recruited for a 1:2 ratio in Greece and Spain. ENVIRONAGE, Belgium, employs a nested case-control design, making use of its prospective cohort framework that is already in place.

  • Personal Exposure Monitoring PEM Substudy

    The study consists of 150 mothers, with 50 from each location. All participants are females aged over 18 years. The sex of the participants is expected to be randomly distributed.

06

What researchers measure

Primary outcomes

  1. Number of PreTerm Births

    Number of total PreTerm Births related to totak births

    Time frame: through study completion, an average of 2 years

Secondary outcomes

  1. Rate of Low Birth Weigth newborns

    Number of total Low Birth Weigth newborns

    Time frame: through study completion, an average of 2 years

Other outcomes

  1. Number of Small for Gestational Age newborns

    Number of total Gestational Age newborns

    Time frame: through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2025
First posted
Nov 20, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 added, 3 removed
What changed in the outcomes
  • AddedNumber of PreTerm BirthsTime frame: through study completion, an average of 2 years
  • RemovedPreTerm BirthTime frame: at the moment of birth
  • RemovedSmall for Gestational AgeTime frame: at the moment of birth
  • RemovedLow Birth WeigthTime frame: at the moment of birth
Nov 16, 2026
Secondary outcomes
2 added
What changed in the outcomes
  • AddedRate of Low Birth Weigth newbornsTime frame: through study completion, an average of 2 years
  • Addedother outcomeNumber of Small for Gestational Age newbornsTime frame: through study completion, an average of 2 years
Nov 16, 2026
Sponsor
Instituto de Investigacion Sanitaria La Fe→Alba Ruiz Gaitán; Collaborators added: European Union
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary outcomes 1 added, 3 removed
    What changed in the outcomes
    • AddedNumber of PreTerm BirthsTime frame: through study completion, an average of 2 years
    • RemovedPreTerm BirthTime frame: at the moment of birth
    • RemovedSmall for Gestational AgeTime frame: at the moment of birth
    • RemovedLow Birth WeigthTime frame: at the moment of birth
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedRate of Low Birth Weigth newbornsTime frame: through study completion, an average of 2 years
    • Addedother outcomeNumber of Small for Gestational Age newbornsTime frame: through study completion, an average of 2 years
    Sponsor Instituto de Investigacion Sanitaria La Fe→Alba Ruiz Gaitán; Collaborators added: European Union
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07238608
Lead sponsor
Alba Ruiz Gaitán
Responsible party
Alba Ruiz Gaitán (Principal Investigator, Instituto de Investigacion Sanitaria La Fe) — Sponsor-investigator
First posted
Nov 20, 2025
Start date
Jan 1, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Alba Ruiz Gaitán, Dr
Contact
alba_ruiz@externos.iislafe.es
0034961246690
Imelda Ontoria Oviedo, Dr
Contact
imelda_ontoria@iislafe.es
0034961246690

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion